Abstract
It is well established that an increase of n-6 polyunsaturated (i.e. arachidonic and arachidonic-converted linoleic acids) fat dietary intake enhances carcinogenesis and promotes tumorigenesis through oxidative metabolism. The Cyclooxygenase (COX) and Lipoxygenase (LOX) enzymes mediate the oxidative metabolism of n-6 polyunsaturated fatty acids and generate a cascade of biological active molecules. Nonsteroidal antinflammatory drugs (NSAIDs) modulating arachidonic acid (AA) metabolism have been utilized in cancer chemoprevention. The gastrolesivity of a prolonged use of nonselective NSAIDs, due to the COX inhibition, an important housekeeping gene of the gastrointestinal system, contraindicated their use in chemoprevention. Moreover, cardiovascular side effects emerged in the long-term use of COX-2 specific inhibitors rising doubts on their use for cancer chemoprevention. This evidence renewed the interest into other AA-metabolizing pathways relevant in inflammation and carcinogenesis. Here, the role of the LOXs pathways in carcinogenesis is reviewed. Inhibition of the LOX pathways, alone or in association with COX-2 pathway, appears to be a promising field for detecting new molecular target and engineering new chemopreventive strategies on cancer.
Keywords: Lipoxygenase inhibitors, cancer prevention, cellular senescence
Current Pharmaceutical Design
Title: Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks
Volume: 16 Issue: 6
Author(s): Cecilia Menna, Fabiola Olivieri, Alfonso Catalano and Antonio Procopio
Affiliation:
Keywords: Lipoxygenase inhibitors, cancer prevention, cellular senescence
Abstract: It is well established that an increase of n-6 polyunsaturated (i.e. arachidonic and arachidonic-converted linoleic acids) fat dietary intake enhances carcinogenesis and promotes tumorigenesis through oxidative metabolism. The Cyclooxygenase (COX) and Lipoxygenase (LOX) enzymes mediate the oxidative metabolism of n-6 polyunsaturated fatty acids and generate a cascade of biological active molecules. Nonsteroidal antinflammatory drugs (NSAIDs) modulating arachidonic acid (AA) metabolism have been utilized in cancer chemoprevention. The gastrolesivity of a prolonged use of nonselective NSAIDs, due to the COX inhibition, an important housekeeping gene of the gastrointestinal system, contraindicated their use in chemoprevention. Moreover, cardiovascular side effects emerged in the long-term use of COX-2 specific inhibitors rising doubts on their use for cancer chemoprevention. This evidence renewed the interest into other AA-metabolizing pathways relevant in inflammation and carcinogenesis. Here, the role of the LOXs pathways in carcinogenesis is reviewed. Inhibition of the LOX pathways, alone or in association with COX-2 pathway, appears to be a promising field for detecting new molecular target and engineering new chemopreventive strategies on cancer.
Export Options
About this article
Cite this article as:
Menna Cecilia, Olivieri Fabiola, Catalano Alfonso and Procopio Antonio, Lipoxygenase Inhibitors for Cancer Prevention: Promises and Risks, Current Pharmaceutical Design 2010; 16 (6) . https://dx.doi.org/10.2174/138161210790883822
DOI https://dx.doi.org/10.2174/138161210790883822 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma
Combinatorial Chemistry & High Throughput Screening Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism Non-Surgical Treatment Options for Symptomatic Uterine Leiomyomas
Current Women`s Health Reviews Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Endometriosis and Gynecological Cancer
Current Women`s Health Reviews Corticotropin Releasing Factor (CRF) Peptide Family and their Receptors: Divergent Actions Influencing Human Physiology
Current Genomics Enzymatic regulation and functional relevance of NOX5
Current Pharmaceutical Design Epigenetics: Relations to Disease and Laboratory Findings
Current Medicinal Chemistry Role of Lycopene in the Control of ROS-Mediated Cell Growth: Implications in Cancer Prevention
Current Medicinal Chemistry Flavonoids, Breast Cancer Chemopreventive and/or Chemotherapeutic Agents
Current Medicinal Chemistry Cytology for the Detection of Early Recurrence of Gynecologic Cancer in the Vaginal Vault
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Histone Deacetylase Inhibition: A Differentiation Therapy for Cultured Primary Hepatocytes?
Current Enzyme Inhibition Current View on the Mechanism of Action of Perifosine in Cancer
Anti-Cancer Agents in Medicinal Chemistry Recent Developments of Platinum-based Anticancer Drugs- Detection and Analysis in Biological Samples
Current Organic Chemistry Pharmacological Inhibitors of Fatty Acid Synthase (FASN)-Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents?
Current Pharmaceutical Biotechnology Assessment of the Usefulness of the SEMA5A Concentration Profile Changes as a Molecular Marker in Endometrial Cancer
Current Pharmaceutical Biotechnology Histone Deacetylase (HDAC) Inhibitors - emerging roles in neuronal memory, learning, synaptic plasticity and neural regeneration
Current Neuropharmacology Recent Patents in Cartilage Regeneration
Recent Patents on Regenerative Medicine Pharmacotherapy for Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Harnessing Impaired Energy Metabolism in Cancer Cell: Small Molecule- Mediated Ways to Regulate Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry